Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?
Is BEAM a good stock to buy? We came across a bullish thesis on Beam Therapeutics Inc. on r/ValueInvesting by Significant-Pair-275. In this article,…
Tag: Therapeutics
Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock
Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best biotech penny stocks to buy in 2026. On April 16, Allogene…
Seaport Therapeutics Said to Raise $255 Million in Upsized IPO
Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized…
Truist Reiterates Buy Rating for Viridian Therapeutics (VRDN)
Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 oversold small cap stocks to buy now. On April 21, Truist…
What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy
Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the 10 oversold small cap stocks to buy now. As of the April…
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?
Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on BioEquity Watch’s Substack. In this article,…
Eli Lilly eyes Kelonia Therapeutics in $7B deal with $3.25B to be paid up front. How to invest early to grow your wealth
Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below. Eli Lilly (NYSE: LLY)…
Travere Therapeutics (TVTX) Climbs 40.8% on Filspari Approval
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 Stocks With Monster Returns. Travere Therapeutics grew its share prices by…
Obesity Firm Kailera Therapeutics Up 63% After $625 Million IPO
Kailera Therapeutics Inc. shares surged 63% after the clinical-stage biotechnology company focused on obesity raised $625 million in an upsized…
CytomX Therapeutics (CTMX) Making Progress on Key Metastatic Colorectal Cancer Treatment
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the best multibagger penny stocks to invest in. On March 23, analysts at…